国际妇产科学杂志

国际妇产科学杂志 ›› 2014, Vol. 41 ›› Issue (3): 304-306.

• 论著 • 上一篇    下一篇

紫杉醇联合奥沙利铂治疗复发性或晚期宫颈癌临床疗效分析

田秀兰，翟建军，冯碧波，王慧香   

  1. 100765　首都医科大学附属北京同仁医院妇产科
  • 收稿日期:1900-01-01 修回日期:1900-01-01 出版日期:2014-06-15 发布日期:2014-06-15

Analysis of the Clinical Effects about Paclitaxel Plus Oxaliplatin in Treatment of Recurrent or Advanced Cervical Cancer

TIAN Xiu-lan，ZHAI Jian-jun，FENG Bi-bo，WANG Hui-xiang   

  1. Department of Obstetrics and Gynecology，Beijing Tongren Hospital Affiliated to Capital Medical University，Beijing 100176，China
  • Received:1900-01-01 Revised:1900-01-01 Published:2014-06-15 Online:2014-06-15

PDF (PC)

5081

摘要： 目的：探讨分析紫杉醇联合奥沙利铂治疗复发性或晚期宫颈癌的临床疗效及不良反应。方法：选取北京同仁医院32例复发性或晚期宫颈癌，给予紫杉醇联合奥沙利铂化疗方案：第1天紫杉醇150 mg/m2静脉滴注≥3 h，第2天奥沙利铂130 mg/m2静脉滴注≥2 h，每21天为1个周期，治疗2个周期后进行评价，评估患者近远期疗效及不良反应。结果：全部患者均可参与评价疗效，总有效率为25.0%，中位无进展生存期（progression-free survival，PFS）和中位总生存期（overall survival，OS）分别为21.2周和52.1周。主要不良反应为神经毒性和骨髓抑制，非血液学不良反应较轻。结论：紫杉醇联合奥沙利铂治疗复发性或晚期宫颈癌患者疗效肯定，不良反应可以耐受，值得进一步临床研究。

关键词: 紫杉酚, 有机铂化合物, 宫颈肿瘤, 肿瘤复发, 局部, 药物疗法, 联合

Abstract: Objective： To investigate the clinical efficacy and adverse reactions of paclitaxel plus oxaliplatin in the treatment of recurrent or advanced cervical cancer. Methods：32 patients of recurrent or advanced cervical cancer were given the chemotherapy of paclitaxel plus oxaliplatin ：the dose of paclitaxel was 150 mg/m2 intravenous infusion ≥3 h in the first day，and the dose of oxaliplatin was 130 mg/m2 intravenous infusion ≥ 2 h in the second day，the course was repeated every 3 weeks，the evaluations of the short term or long term and adverse reactions were evaluated after 2 cycles treatment. Results：All patients can participate in the evaluation of curative effect，and the total effective rate was 25%. The median progression free survival and median overall survival were 21.2 weeks and 52.1 weeks respectively. The main adverse reactions were toxicities and myelosuppression，non-hematologic adverse reaction was mild. Conclusions：Paclitaxel plus oxaliplatin has quite valid curative effect on the treatment of recurrent or advanced cervical cancer patients，the adverse reactions can be tolerated，which was worthy for the further clinical research.

Key words: Paclitaxel, Organoplatinum compounds, Uterine cervical neoplasms, Neoplasm recurrence, local, Drug therapy